Landscapes / Companies

Vanda Pharmaceuticals not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 approved
1 in Phase 3
Next date
Tradipitant, Phase 3 trial completes
Drugs
9
in active trials · 12 in all
Trials
15 active
55 since 2021

Drugs9

DrugHow it worksPartnerStageNext dateDetails
—
Approved 1 Dec 2026soonPhase 3 trial completes
Atypical antipsychotic
Approved Nov 2027Phase 3 trial completes
Melatonin receptor agonist
Approved Nov 2027Phase 3 trial completes
—
Approved Mar 2028Phase 3 trial completes
Sphingosine 1-phosphate receptor modulator
Actelion
Approved Aug 2028Phase 3 trial completes
—
Phase 3 Dec 2026Phase 3 trial completes
—
Phase 1/2 Mar 2027Phase 1/2 trial completes
—
Phase 2 Dec 2027Phase 1 trial completes
—
Phase 2 —

About

No active trial
Double-blind, Imsidolimab, Open-label
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Vanda Pharmaceuticals

Following is part of Solo: you see every change to Vanda Pharmaceuticals the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in